NewGenIvf's latest reverse split leaves a $7.1 million note on a reset clock

Summary: U.S. short Watchlist. NewGenIvf Group Limited (Nasdaq: NIVF) was marked at $1.33 in the latest finance-feed context at 2026-09-01 20:45:00 UTC, down 1.41576%, after an intraday range of $1.305 to $1.43 and 63,105 shares. StockAnalysis records a $1.35 Sep. 1 regular close and a $1.35 early after-hours mark. That small but real quote difference, the post-split share basis, and missing top-of-book data block execution. The company made its latest 1-for-3 reverse stock split effective on Sep. 1, after six earlier consolidations from February 2025 through July 2026. On Aug. 14, it exchanged older instruments for a new $7,105,468.75 senior convertible note with a $0.5517 initial conversion price before the Sep. 1 split, a 9.99% beneficial-ownership cap, and a leak-out limit. The note terms say a share-combination event can reduce the conversion price to the event market price on the sixteenth trading day after the event if the event market price is below the adjusted conversion price. The last reviewed filing reported $758,621 of cash at Dec. 31, 2025, $10.926 million of 2025 operating cash use, and a $21.7 million bargain-purchase gain that helped produce reported profit. The short thesis is that the market may price the reverse split as balance-sheet repair while a senior conversion claim, future equity financing, and cash burn remain unresolved. This is reference-only research, not an executable short or personalized financial advice.

Run timestamp: 2026-09-02T05:30:27+08:00 (Asia/Singapore). Quote timestamps below are separate from publication time.

Opportunity Ranking

Rank	Candidate	Direction	Mispricing	Evidence Freshness	Catalyst Window	Positioning	10/5 Status	Tradeability	Main Rejection Risk
1	NewGenIvf Group (NIVF)	Short	The Sep. 1 reverse split can make a small quoted price look repaired, while a $7.1 million senior convert, a possible sixteenth-trading-day conversion reset, serial share consolidations, and negative operating cash leave the capital stack unresolved	Aug. 20 F-1, Aug. 17 6-K and note documents, Sep. 1 corporate action and market data, Dec. 31 audited cash-flow data	First post-split sessions, note reset window around Sep. 24, registration or conversion, and next cash and share-count filing	Public feeds disagree between 8.9K and 171.6K short shares because the denominator and split basis are not reconciled; borrow about 70.6% to 73.71% with 250K available in public snapshots	Watchlist; reject for current execution	63K shares in the latest finance feed, but regular and after-hours marks differ and spread, depth, venue, and exit liquidity are unverified	The exchange removed the old proceeds sweep, the note stays subject to leak-out and ownership caps, and the reverse split stabilizes the quote
2	Kairos Pharma (KAPA)	Short	A 1-for-7 split lifts the quote while the latest 10-Q still shows no revenue, $2.626 million cash, $2.048 million of first-half operating cash use, and substantial doubt about funding	Aug. 12 10-Q, Aug. 21 reverse-split filing, Sep. 1 price and borrow data	Post-split price acceptance, financing, and the next clinical or cash disclosure	364.2K shares short, 10.8% of shares, 1.0 day to cover, and 13.8% borrow with 1.2M public availability; current locate is absent	Watchlist alternative; reject	69,849 shares on Sep. 1 history, but current spread, depth, and exit evidence are missing	Phase 1 safety data, Bayer collaboration, or a new financing can support the clinical story
3	Lucas GC (LGCL)	Short	A 125-for-1 consolidation and a $25 million ATM sit beside a future AI PaaS narrative, but the business has filed revenue, the current share basis is confused, and borrow is punitive	Aug. 28 6-K, Aug. 7 ATM prospectus, Apr. 20 20-F, Sep. 1 market data	First post-split resale or ATM sale and denominator reconciliation	Borrow around 457.18% with 230K pre-split short shares in public context; post-split basis and account-level locate are unresolved	Reject	769,541 shares in a finance-feed context, but provider market cap and post-split share count conflict	The company has real 2025 revenue and the 125-for-1 adjustment may be only a unit translation

Candidate evidence uses the NewGenIvf Aug. 17 financing 6-K, the Kairos Pharma Aug. 12 10-Q, and the Lucas GC Aug. 28 share-consolidation 6-K. Price and positioning references are listed in the Sources section.

Selected opportunity: NewGenIvf Group Limited (NIVF), Nasdaq Capital Market Class A ordinary shares.

Why this one now: NIVF has the clearest short-side event path among the fresh candidates. The Sep. 1 split is complete, the note is already issued, the conversion price is contractually affected by the split, and the sixteenth-trading-day reset is a dated test. KAPA has a cleaner cash deficit but less immediate claim mechanics. LGCL has a more dramatic consolidation and ATM mismatch, but its filed revenue and post-split share-basis conflict make the direction less defensible. NIVF ranks first as a research opportunity, not as an executable short.

What should surprise the reader: A reverse split does not pay a note, create cash, or turn a bargain-purchase gain into operating cash. The more unusual risk is not merely dilution. The note can become economically more aggressive if the post-split event market price stays below the adjusted conversion price, but the holder's leak-out, registration, ownership, and settlement constraints decide whether that claim becomes actual resale supply.

Why This Is the Best Opportunity Right Now

The fresh event is a capital-structure sequence rather than a single headline. NewGenIvf's Aug. 20 preliminary F-1 says the company had 6,367,870 Class A ordinary shares and 37,925 Class B ordinary shares outstanding on Aug. 19. The Sep. 1 1-for-3 reverse split mechanically implies approximately 2,122,623 Class A shares and 12,642 Class B shares, before rounding and any later issuance. That is a calculation from a dated pre-split count, not a verified current denominator. NewGenIvf Aug. 20 F-1 and Nasdaq corporate-action notice

The note exchange adds a dated economic test. On Aug. 14, NewGenIvf issued a new senior convertible note with an original principal amount of $7,105,468.75 in exchange for older notes and related warrants. The note states an initial conversion price of $0.5517, subject to adjustment. It also states that a share-combination event proportionately increases the conversion price, and that if the event market price is below the conversion price after that adjustment, the conversion price can be reduced to the event market price on the sixteenth trading day immediately following the share-combination event. A 1-for-3 split would mechanically move the initial conversion price to approximately $1.6551 before any later reset. The current finance-feed context is below that level. NewGenIvf note

The contract does not make the entire principal immediately tradable. The holder is subject to a 9.99% beneficial-ownership limit. The Aug. 14 leak-out agreement limits open-market sales during the restricted period to the greater of $550,000 or 20% of average daily composite volume in the applicable month, with exceptions for certain off-market transfers. The note also requires the company to reserve shares for full conversion at the applicable floor price. These protections are a real counterparty argument and a reason not to treat the principal divided by price as current float. NewGenIvf leak-out agreement

The operating evidence is older but unusually revealing. NewGenIvf's 2025 Form 20-F reports $4.726 million of revenue, down 13.01% from 2024, and $955,846 of gross profit. It reports $9.7287 million of net income, but the same filing attributes the difference between profit and operating cash to a $21.7 million bargain-purchase gain from the Nodexus and MicroSort acquisitions. Operating cash flow was negative $10.926 million, investing cash use was $7.560 million, and cash at year-end was $758,621. The company says future liquidity depends on operations and external financing. NewGenIvf 2025 Form 20-F

NIVF has no dedicated article or signal in the current repository. It is not one of the current-week TDW, CVKD, MDT, GTLB, FNGR, ASAN, or SNOW theses. KAPA and LGCL also had no dedicated article or signal in the current-week archive. The new thesis is bounded by the Sep. 1 corporate action, the Aug. 14 note exchange, and the current share, cash, and operating evidence. The prior repository search for similar serial reverse-split and convert setups was used for duplication control, not as a substitute for current sources.

Why This Can Move More Than 5% Soon

The share combination itself is not a bearish return. It changes the quoted unit. The price test is whether a post-split quote can hold while the market absorbs a senior note whose pre-split conversion price was $0.5517 and whose conversion mechanics now reference a post-split price below approximately $1.6551. The sixteenth trading day after Sep. 1 falls around Sep. 24, excluding the U.S. Labor Day holiday, but the contract and the issuer's filings remain the authority for the exact event state.

At the latest $1.33 reference, dividing the note's original principal by the price produces a simple quotient of approximately 5.34 million shares before ownership caps, resets, registration, settlement, or leak-out limits. Compared with approximately 2.12 million post-split Class A shares implied by the Aug. 19 count, that is a stress ratio of about 2.5 times. It is not a prediction of issuance. It is the reason the note, the current denominator, and the post-split price cannot be analyzed separately.

The next move can also be discontinuous. A note conversion, financing, exchange notice, registration event, or strategic investment can arrive while the available borrow is limited and the float is small. Conversely, a holder that retains the note, a company that raises non-dilutive cash, or a clean post-split price acceptance can invalidate the simple supply story. The cheapest falsification is the next filed conversion, cash receipt, registration, and share-count update, not a technical support line.

10/5 Asymmetry Gate

The holding window is Sep. 1 through Sep. 24, 2026, covering the first post-split regular sessions, any financing or conversion, the sixteenth-trading-day conversion-price test, and the earliest available cash and denominator reconciliation. The $1.33 mark is the latest finance-feed context, not a verified executable entry.

Test	Calculation or evidence	Result
Reference price	$1.33 at 2026-09-01 20:45:00 UTC; finance-feed context	Reference only
Favorable base move	Short from $1.33 to $0.85: (1.33 - 0.85) / 1.33	+36.09% before costs
Credible adverse move	Short from $1.33 to $2.75: (2.75 - 1.33) / 1.33	-106.77% before costs
Gross favorable-to-adverse ratio	36.09% / 106.77%	0.34:1, below 2:1
Indicative carry	73.71% annualized borrow snapshot from Sep. 1, if unchanged for 23 calendar days	About 4.64% of notional before spread, fees, recall, buy-in, and path effects; actual broker terms are unverified
After-cost value	Current locate, conversion, registration, settlement, spread, depth, venue, and exit states are not verified	Cannot compute responsibly
Measurement basis	Verified entry or reference-only	Reference-only
Classification	10/5 downside and execution gates	Watchlist; reject for current trade

The base decline clears 10%, but the credible adverse rise is more than 100% and the ratio is far below 2:1. Even the reference-only weighted outcome is not a green light: the price-only weighted target is $1.155, or an expected short return of about 13.16% before costs, while indicative borrow alone could consume roughly 4.64% if unchanged. The missing execution and claim-state evidence prevents a responsible after-cost EV and fails the Desk's 10/5 trade-qualified standard.

What Should Surprise the Reader

The Sep. 1 action is the eighth reverse stock split in the sequence disclosed by NewGenIvf's Aug. 20 F-1, counting the six actions from February 2025 through March 2026, the July 6, 2026 split, and the Sep. 1 split. Serial consolidation is a record of capital-structure pressure, not proof of fraud or inevitable price decay. It also makes unadjusted share-count and short-interest data dangerous to compare.

The reported 2025 profit is not the same as operating cash. The filing's $21.7 million bargain-purchase gain helped create net income of $9.7287 million, while operating cash was negative $10.926 million. The company also used $7.560 million in investing activities, including real-estate reservation money, digital assets, custody investments, and acquisition cash. A profitable income statement can therefore coexist with a financing-dependent cash position.

The note's conversion-price reset is not automatic supply. The holder can convert subject to the 9.99% cap, registration and market conditions, and the leak-out schedule. The correct question is whether the Sep. 1 price remains below the adjusted conversion price through the relevant test, whether a registration statement is available, whether the holder submits a conversion, how much can settle, and whether actual resale follows. The public documents do not yet answer all of those questions.

The Setup

NewGenIvf is a British Virgin Islands holding company with assisted reproductive services in Thailand, Cambodia, and Kyrgyzstan, alongside a MicroSort business and newer strategic investments. The company describes fertility treatment, referral services, technology, digital assets, and real-estate development as parts of a diversified growth strategy. Those businesses may have value. The short thesis is narrower: the latest public equity unit has been compressed again while the senior claim and cash bridge remain unresolved.

The Aug. 14 exchange removed the prior mandatory proceeds sweep described by the company, which gives NewGenIvf more financing flexibility. It did not remove the $7.105 million senior principal. The new note matures on Oct. 1, 2027, has no ordinary interest unless an event of default occurs, and can be converted at the contract price or an alternate price subject to the stated terms. The note can therefore be a funding runway tool for the company and a potential share claim for the holder at the same time.

The latest preliminary F-1 is also a future financing state, not current issuance. It proposes an offering of Class A ordinary shares or pre-funded warrants with quantities and price marked as [●] in the reviewed document. Registration of a potential offering does not prove that the securities were sold, that proceeds were received, or that the holder will resell. The older White Lion and JAK resale prospectus registers up to 100 million Class A shares under several prior claims, but that headline is also not a current-float number. NewGenIvf preliminary F-1 and NewGenIvf resale prospectus

The useful state ladder is:

The Sep. 1 reverse split is an effective unit change.
The Aug. 14 senior note exchange is a completed financing restructuring.
The note's conversion and leak-out terms are contractual claims, not current common shares.
The Aug. 20 F-1 is a preliminary future offering with no priced quantity in the reviewed document.
A registration, conversion, settlement, resale, cash receipt, and current denominator remain separate future tests.

The Market Price

Observation	Value	Timestamp / session	Source and limitation
Latest finance-feed price	$1.33	2026-09-01 20:45:00 UTC; after-hours context after the regular session	NIVF finance-feed quote; session state, bid, ask, and venue are not independently verified
Finance-feed change	-$0.01910, -1.41576%	Same observation	NIVF finance-feed quote; provider context
Finance-feed open / high / low	$1.31 / $1.43 / $1.305	Same observation	NIVF finance-feed quote; range fields are not an order-book audit
Finance-feed volume	63,105 shares	Same observation	NIVF finance-feed quote; venue and volume quality are unverified
Finance-feed market-cap context	$13,498,685	Same observation	NIVF finance-feed quote; does not reconcile with the post-split share arithmetic or StockAnalysis field
Regular-session close	$1.35 close; $1.43 high; $1.31 low; $1.35 open; 61,017 shares; +0.07%	Sep. 1, 2026 at 4:00 p.m. Eastern Time	NIVF price history; daily history, not a live order-book audit
Early after-hours context	$1.35, up 1.50%	Sep. 1, 2026 at 4:13 p.m. Eastern Time	NIVF price history; differs from the later finance-feed mark
Aug. 31 regular-session close	$1.35; +6.64%; 141,261 shares	Aug. 31, 2026	NIVF price history; pre-split-event context, with the split basis requiring reconciliation
Latest filed pre-split denominator	6,367,870 Class A and 37,925 Class B shares	Aug. 19, 2026	NIVF Aug. 20 F-1; post-split and post-event issuance not verified

I use $1.33 as the reference because it is the latest available finance-feed observation. I do not treat it as an executable entry. The $1.35 regular and early after-hours marks, the later $1.33 context, the provider market-cap conflict, the post-split denominator, and missing top-of-book data require a fresh regular-session audit.

The Mispricing

The market is being asked to price five states as if they were one:

A reverse split that mechanically raises the quote.
A completed note exchange that removes the old proceeds sweep.
A $7.105 million senior conversion claim with a price-reset clause.
A preliminary F-1 for future common or pre-funded securities.
A fertility-services business with 2025 revenue but negative operating cash and a profit materially aided by a bargain-purchase gain.

The mispricing is an inference, not a direct observation: the post-split quote may be read as an equity repair event even though the company still has to show cash, operating conversion, current claims, registration, note settlement, and a stable denominator. The market may be right to value the reverse split as a useful listing and financing tool. It may also be right that a leak-out clause slows selling enough to protect the quote. The short case only exists if those protections are capitalized faster than the senior-claim and cash evidence improves.

No enterprise value or current per-share fair value is computed. The latest audited cash is Dec. 31, the latest common-share count is Aug. 19 and pre-split, the provider market-cap fields disagree, the current F-1 is preliminary, and the note conversion and resale states are unobserved. The correct output is a price-only scenario map with explicit claim and cash states.

The Positioning

ShortInterestTracker's Sep. 1 page reports 8,932 shares short, 0.26% of shares outstanding, and 250,000 shares available at a 73.71% borrow fee, using the July 31 FINRA settlement for short interest. CurvedTrading's Aug. 31 page reports 171,641 shares short, 71.3% of shares outstanding, 1.0 day to cover, 250,000 shares available, and a 70.6% borrow fee, using the Aug. 14 FINRA settlement and a different split or denominator treatment. StockAnalysis reports 171,641 shares and 8.04% of outstanding shares. These cannot be treated as one current positioning truth without a share-basis reconciliation. NIVF Short Interest Tracker, NIVF CurvedTrading context, and NIVF statistics

The positioning score is 2/5. There is direct evidence of expensive and limited public borrow, but the short-interest percentages conflict sharply. The most plausible explanation is an unresolved split and denominator normalization issue, but that is an inference. Current holder flow, utilization, account-level locate, recall terms, and reliable post-split depth are missing. The reported short data is a reason to stress the squeeze case, not to assume that the current price must fall.

The Catalyst

Catalyst	State and timing	Observable test	Directional implication
First post-split price acceptance	Sep. 1 effective 1-for-3 split; first regular sessions are the next market test	Verify regular-session quote, bid, ask, spread, depth, venue, volume quality, and exit liquidity; compare the $1.33 context with the $1.35 close	Holding with new cash or operating evidence supports the counterparty; fading without new proof supports the thesis
Adjusted conversion-price clock	The note's initial $0.5517 price is mechanically adjusted for the 1-for-3 combination to about $1.6551 before later terms	Verify the contract's share-combination adjustment and whether event market price remains below the adjusted conversion price	A lower event price can increase the potential share claim; a price above or a term-based exception removes the reset path
Sixteenth trading-day test	The note provides for a possible conversion-price reduction on the sixteenth trading day immediately following the share-combination event if the event market price is below the adjusted conversion price; approximately Sep. 24, excluding the Sep. 7 holiday	Verify the exact trading-day count, event market price, floor, conversion price, and any notice or exception	A reset can increase conversion pressure; holder retention, registration failure, or repayment supports the squeeze case
Note conversion and leak-out	Aug. 14 exchange completed; $7.105 million principal remains subject to 9.99% cap and the greater-of-$550K or 20% volume monthly leak-out limit	Verify conversion notice, registration availability, settled shares, sales volume, and remaining principal	Actual settlement and resale can pressure price; no conversion or holder retention removes the supply path
Preliminary equity financing	Aug. 20 F-1 contains an unpriced offering of Class A shares or pre-funded warrants	Verify effectiveness, final price and quantity, closing, cash receipt, and post-offering denominator	Financing can extend runway while adding supply; failure or weak terms supports the cash concern
Cash and operating bridge	Latest audited cash and operating cash are Dec. 31, 2025; no current 2026 cash filing reviewed	Require current cash, debt, note claims, revenue, margin, operating cash, and current shares	Collected cash and positive operating conversion invalidate the cash-burn thesis; continued financing dependence supports it

The cheapest falsification sequence is the first regular-session tape, the exact post-split denominator, the note's sixteenth-day calculation, registration and conversion notices, actual settlement and resale, and the next cash-flow filing. A reverse split or preliminary F-1 should not outrank those tests.

The Payoff

The payoff map is price-only because the entry, current post-split denominator, note conversion state, registration, holder flow, and after-cost short terms are not verified.

Scenario	Probability	Target / Level	Return / Payoff	Horizon	Conditions	Evidence Quality
Top Case	30%	$0.60	+54.89% short return before costs	By Sep. 24, 2026	The note reset or another claim becomes visible, no new financing improves the cash bridge, and post-split attention fades	Medium
Base Case	50%	$0.85	+36.09% short return before costs	By Sep. 24, 2026	The reverse split holds only temporarily, the note remains a future supply claim, and operating cash and current denominator remain unresolved	Medium
Bottom Case	20%	$2.75	-106.77% short return before costs	During the post-split and note window	The exchange removes financing friction, the holder retains or transfers the note without resale pressure, current cash improves, a new offering is absorbed, or momentum buyers squeeze the limited float	Low to Medium
Invalidation	n/a	A current filing shows note repayment or durable holder retention, positive operating cash, adequate current liquidity, a stable denominator, and post-split price acceptance	Remove the thesis and do not wait for a price stop	As observed	The market has evidence that the reverse split and financing flexibility are supported by current cash and operating conversion	High when filed

Probability-weighted expected value: Price-only weighted target = (0.30 x $0.60) + (0.50 x $0.85) + (0.20 x $2.75) = $1.155. Against the $1.33 reference, that is an expected short return of 13.16% before borrow, spread, slippage, fees, recall, funding, and path effects. Indicative 73.71% borrow for 23 calendar days would consume roughly 4.64% if unchanged, but after-cost EV cannot be computed responsibly because the broker locate, current borrow terms, conversion and registration state, post-split denominator, spread, depth, and exit liquidity are unverified.

Current market level and timestamp: $1.33 finance-feed context at 2026-09-01 20:45:00 UTC; regular-session close $1.35 at Sep. 1 4:00 p.m. Eastern Time.

Primary instrument: NIVF Class A ordinary shares only, if every future gate is independently verified.

10/5 favorable base move: 36.09% decline from the reference-only mark.

10/5 credible adverse move: 106.77% underlying rise to the bottom-case level.

10/5 measurement basis: Reference-only, not verified entry.

10/5 status: Watchlist for research; Reject for current execution.

Confidence: Medium on the Sep. 1 split, Aug. 14 note exchange, note reset language, Aug. 19 share count, and 2025 audited cash-flow data. Low to Medium on current cash, current denominator, exact post-split claim ledger, registration, conversion, holder flow, borrow normalization, and the probability map.

The Kill Shot

The strongest counterparty argument is that the Aug. 14 exchange made the capital stack less immediately punitive. NewGenIvf says the restructuring removed the prior mandatory proceeds sweep, and the note has a leak-out arrangement rather than an unrestricted sale right. The company operates real fertility clinics, receives some customer payments before services, and reported revenue and gross profit in 2025. The reverse split can improve quote optics and listing flexibility. A holder can retain the note, sell it off-market subject to a new leak-out agreement, or wait for a better price. In that case, the potential conversion quotient never becomes near-term common supply.

That argument is serious. The short can lose even if operating cash remains weak because a small post-split float can move on a modest amount of demand. The load-bearing assumption is not that the note must convert on Sep. 24. It is that the market will need fresh evidence of cash, claim settlement, and operating conversion before sustaining the post-split quote. A current filing showing note repayment or durable holder retention, positive operating cash, and stable shares invalidates the thesis.

What Could Go Wrong

The note holder does not convert, respects the leak-out, and provides or receives an off-market transfer that does not pressure the common.
NewGenIvf raises non-dilutive capital, collects customer cash, or improves operating cash before the reset window.
The 1-for-3 split restores listing optics and attracts momentum buyers into a small post-split share base.
The sixteenth-trading-day reset does not apply because the exact event market price, floor, registration, or other contractual condition is not satisfied.
A new financing has favorable terms, enough cash, or a strategic investor that the market values above the supply risk.
The Aug. 19 share count is stale, the actual post-split denominator differs, or a data vendor has not normalized the corporate action.
The provider's 0.26%, 8.04%, and 71.3% short-interest figures reflect different split bases rather than a true short squeeze setup.
Borrow becomes unavailable, the fee rises, shares are recalled, or the broker cannot maintain the locate through a note or financing notice.
The stock gaps through an exit, trades through a halt, or loses depth when the 63K to 245K daily-volume context disappears.
A positive fertility result, strategic investment, or acquisition announcement creates demand before current cash and claims are fully reconciled.

What Would Prove This Wrong

The thesis is invalidated by a current filed sequence showing: the post-split common and Class B denominator; the note balance, conversion price, registration, conversion, and resale state; note repayment or durable holder retention; cash after operating needs and financing; positive or improving operating cash; and regular-session price acceptance with reliable liquidity. A reverse split, an unpriced F-1, an earnings estimate, or a management statement alone is not enough.

Execution is independently cancelled if a broker cannot provide a current locate, borrow fee, utilization, recall and buy-in terms, or if the regular-session quote, spread, depth, venue, volume quality, and exit-liquidity audit is unacceptable. The price-only map remains non-executable even if the note reset path appears mechanically attractive.

Risk Audit

Risk	Current evidence	Control
Reverse-split illusion	Sep. 1 1-for-3 split changes quote units and post-split claims but does not create cash or repay senior debt	Reconcile pre- and post-split shares, claims, quote, and CUSIP before using price comparisons
Conversion reset	Note starts at $0.5517 before split, adjusts with the share combination, and may reset on the sixteenth trading day if conditions hold	Verify exact contract calculation, event market price, floor, registration, conversion notice, and settlement
Seniority and leak-out	$7.105 million senior principal remains; holder is subject to 9.99% cap and a greater-of-$550K or 20% volume leak-out	Model claim, settlement, resale, and holder retention as separate states; do not call principal current float
Cash quality	Dec. 31 cash $758,621; 2025 operating cash use $10.926 million; 2025 investing cash use $7.560 million	Require current cash, debt, operating cash, note balance, and cash after financing
Non-operating profit	$21.7 million bargain-purchase gain helped produce $9.729 million 2025 net income	Use operating cash and recurring revenue, not headline profit, as the adjudicating test
Future equity financing	Aug. 20 F-1 has unpriced Class A or pre-funded securities with blank quantity fields	Verify effectiveness, final price, quantity, close, cash receipt, and post-offering denominator
Resale claims	Older White Lion and JAK prospectus registers up to 100 million shares under several claims	Separate registration from conversion, settlement, holder resale, and actual supply
Positioning data	Public sources report 8.9K, 171.6K, and 171.6K short shares using incompatible share bases	Cap positioning at 2/5; require current locate, utilization, recall, and post-split holder flow
Borrow and recall	Public borrow fee is about 70.6% to 73.71% with 250K availability in dated snapshots; no account-level locate	No entry without current broker terms and carry through the reset window
Market structure	Finance feed shows $1.33 while regular and early after-hours history shows $1.35; bid, ask, spread, depth, venue, and exit are missing	Use a fresh regular-session audit; no after-hours short, market order, leverage, or halt entry
Gap and squeeze	Small post-split share base, corporate actions, financing, and note notices can move price discontinuously	Keep entry null, assume gaps can bypass controls, and re-underwrite after every filing

Best Trade Strategy

This is a Watchlist research expression, not an executable trade.

Instrument: NIVF Class A ordinary shares only. No options, leverage, margin, or market order is supported by the current evidence.
Price basis: The reference is $1.33 at 2026-09-01 20:45:00 UTC. It is not an executable entry.
Entry state: entry.price = null. execution.can_execute = false.
Required market gates: fresh regular-session quote, bid, ask, spread, reliable depth, venue quality, volume quality, realistic exit liquidity, and resolution of the $1.33 versus $1.35 context.
Required short gates: broker-level locate, borrow fee, utilization, recall and buy-in terms, settlement state, and availability through the sixteenth-trading-day test and first resale.
Required fundamental gates: current post-split Class A and Class B denominator, note balance and conversion price, leak-out and registration state, actual conversion or repayment, F-1 effectiveness and proceeds, current cash, operating cash, and customer collection evidence.
Conditional targets: $0.60 top, $0.85 base, and $2.75 bottom are scenario levels only. They are not guaranteed exits or trade instructions.
Horizon: Sep. 1 through Sep. 24, 2026. Re-underwrite after the first regular-session tape, the exact sixteenth-trading-day calculation, any note notice, financing, registration, resale, and the next cash-flow filing.
Do not trade: Do not short the post-split after-hours mark or through a halt. Do not treat the reverse split, unpriced F-1, resale registration, note principal, reported profit, or provider market cap as proof of current supply, cash, or a price floor. Do not use options or leverage without a separately verified live chain, spread, assignment, and maximum-loss analysis.

Sources

NewGenIvf Aug. 17, 2026 Form 6-K - Aug. 14 senior-note exchange, leak-out agreement, and filing state.
NewGenIvf senior convertible note - $7,105,468.75 principal, $0.5517 initial conversion price, 9.99% ownership cap, share-combination and sixteenth-trading-day reset terms, and maturity.
NewGenIvf leak-out agreement - greater-of-$550,000 or 20% average-volume monthly sale limit and off-market transfer conditions.
NewGenIvf Aug. 20, 2026 preliminary Form F-1 - Aug. 19 pre-split Class A and Class B count, unpriced future offering, share history, and risk factors.
Nasdaq corporate-action notice for NIVF - Sep. 1, 2026 1-for-3 reverse split and CUSIP change.
NewGenIvf 2025 Form 20-F - 2025 revenue, gross profit, bargain-purchase gain, operating and investing cash use, year-end cash, and financing history.
NewGenIvf resale Form 424B3 - up to 100 million registered resale claims and White Lion and JAK claim components.
NIVF finance-feed quote - latest price, range, change, volume, and provider market-cap context at 2026-09-01 20:45:00 UTC.
NIVF regular-session and after-hours history - Sep. 1 regular close, early after-hours mark, Aug. 31 context, and volume.
NIVF statistics - provider market-cap, enterprise-value, short-interest, operating-cash, and share-basis context.
NIVF Short Interest Tracker - Sep. 1 borrow fee and availability plus July 31 FINRA short-interest snapshot.
NIVF CurvedTrading context and NIVF public borrow history - Aug. 31 borrow, short-interest, threshold, and availability context using a different split basis.
Kairos Pharma Aug. 12, 2026 Form 10-Q - ranked KAPA alternative cash, revenue, operating cash, and share count.
Kairos Pharma Aug. 21 reverse-split filing, KAPA price history, and KAPA borrow context - ranked alternative corporate action, market, short, and borrow data.
Lucas GC Aug. 28, 2026 Form 6-K, Lucas GC ATM prospectus, and LGCL borrow context - ranked alternative consolidation, financing, and borrow data.

Research Quality Scorecard

Criterion	Score	Reason
Market disagreement	4/5	The quote is split-adjusted while the senior conversion claim, cash state, and current denominator remain unresolved
Evidence base	4/5	Current corporate-action and note documents are paired with an Aug. 19 share count, audited cash-flow data, and current market history
Positioning and flows	2/5	Borrow is expensive and limited in public snapshots, but short-interest percentages conflict and holder flow and depth are missing
Catalyst path	4/5	First post-split acceptance, a contractual sixteenth-trading-day test, registration, conversion, resale, and cash filing are observable
Payoff architecture	3/5	The base decline exceeds 10%, but the adverse case is large and the gross ratio is below 2:1
Invalidation discipline	4/5	Repayment, holder retention, current cash, operating conversion, denominator, registration, and price acceptance tests are explicit
Differentiated insight	5/5	Separates reverse-split units, senior claims, conversion reset, leak-out, non-operating profit, and cash flow
Client value	4/5	The note and denominator ladder is useful even though it blocks an executable short

Total: 30/40. Classification: Watchlist. The score cannot override the failed 10/5 adverse bound, the split-basis positioning conflict, the stale cash bridge, or incomplete short-side execution evidence.

Bottom Line

NIVF is the strongest fresh U.S.-short research candidate because the Sep. 1 reverse split creates an observable conversion-price test around the sixteenth trading day, while the Aug. 14 senior note and the last audited cash-flow statement expose a funding and denominator problem. The differentiated point is not that the fertility business has no value or that the note must convert. It is that a reverse split can change the quote without changing cash, seniority, or current operating conversion. Until the post-split denominator, note registration and settlement, current cash, borrow, holder flow, and regular-session liquidity are verified, the correct state is Watchlist with no executable entry.

AI Illustration Prompt

Create a realistic editorial illustration for The Mispricing Desk about NewGenIvf Group (NIVF): a quiet securities-processing room immediately after a reverse stock split, with a large mechanical counter changing from 1:3 to a higher quoted price while the underlying cash drawer stays nearly empty. In the foreground, show a senior convertible note folder labeled $7.105M SENIOR NOTE / $0.5517 PRE-SPLIT CONVERSION PRICE / 9.99% CAP feeding into a precise clock face marked 16TH TRADING DAY AFTER SEP 1, with a small amber indicator reading RESET CONDITION PENDING. Beside it, place a translucent share ledger showing 6.368M CLASS A PRE-SPLIT, ~2.123M POST-SPLIT IMPLIED, and CURRENT DENOMINATOR UNVERIFIED, plus a separate leak-out card marked GREATER OF $550K OR 20% AVG VOLUME. In the background, show a restrained fertility clinic corridor and three small operating documents labeled 2025 REVENUE $4.726M, 2025 OCF -$10.926M, and YEAR-END CASH $0.759M, with a visible note that $21.7M BARGAIN-PURCHASE GAIN IS NOT OPERATING CASH. A market monitor shows two close but conflicting readings, $1.35 REGULAR CLOSE and $1.33 LATEST CONTEXT, while a red stamp says ENTRY UNVERIFIED. Make the distinction between reverse-split quote optics, senior claim, conversion reset, leak-out, cash flow, and current float visually unmistakable. Use charcoal, warm paper, muted clinical teal, cobalt, brushed aluminum, off-white, and one controlled red accent; documentary financial-journalism lighting; tactile paper, glass, steel, and quiet clinic textures; no rockets, coins, generic candlestick charts, hype imagery, invented logos, or personalized advice. Add a subtle readable The Mispricing Desk watermark on the room wall. Wide 16:9 composition, premium magazine art direction, precise typography, sober and unresolved.